Stereoselective modulatory actions of oleamide on GABAA receptors and voltage‐gated Na+ channels in vitro: a putative endogenous ligand for depressant drug sites in CNS

British Journal of Pharmacology - Tập 129 Số 2 - Trang 283-290 - 2000
Bernard Verdon1, Jian Zheng2, Russell A. Nicholson2, C Robin Ganelli3, George Lees1
1Institute of Pharmacy and Chemistry, School of Sciences, University of Sunderland, Wharncliffe Street, Sunderland SR2 3SD
2Department of Biological Sciences, Simon Fraser University, 8888 University Drive, Burnaby, British Columbia V5A 1S6, Canada
3Department of Chemistry, University College London, Christopher Ingold Laboratories, 20 Gordon Street, London

Tóm tắt

cis‐9,10‐octadecenoamide (‘oleamide’) accumulates in CSF on sleep deprivation. It induces sleep in animals (the trans form is inactive) but its cellular actions are poorly characterized. We have used electrophysiology in cultures from embryonic rat cortex and biochemical studies in mouse nerve preparations to address these issues. Twenty μM cis‐oleamide (but not trans) reversibly enhanced GABAA currents and depressed the frequency of spontaneous excitatory and inhibitory synaptic activity in cultured networks. cis‐oleamide stereoselectively blocked veratridine‐induced (but not K+‐induced) depolarisation of mouse synaptoneurosomes (IC50, 13.9 μM). The cis isomer stereoselectively blocked veratridine‐induced (but not K+‐induced) [3H]‐GABA release from mouse synaptosomes (IC50, 4.6 μM). At 20 μM cis‐oleamide, but not trans, produced a marked inhibition of Na+ channel‐dependent rises in intrasynaptosomal Ca2+. The physiological significance of these observations was examined by isolating Na+ spikes in cultured pyramidal neurones. Sixty‐four μM cis‐oleamide did not significantly alter the amplitude, rate of rise or duration of unitary action potentials (1 Hz). cis‐Oleamide stereoselectively suppressed sustained repetitive firing (SRF) in these cells with an EC50 of 4.1 μM suggesting a frequency‐ or state‐dependent block of voltage‐gated Na+ channels. Oleamide is a stereoselective modulator of both postsynaptic GABAA receptors and presynaptic or somatic voltage‐gated Na+ channels which are crucial for synaptic inhibition and conduction. The modulatory actions are strikingly similar to those displayed by sedative or anticonvulsant barbiturates and a variety of general anaesthetics. Oleamide may represent an endogenous modulator for drug receptors and an important regulator of arousal. British Journal of Pharmacology (2000) 129, 283–290; doi:10.1038/sj.bjp.0703051

Từ khóa


Tài liệu tham khảo

10.1016/0005-2736(82)90070-0

10.1097/00001756-199904060-00010

10.1016/S0920-1211(98)00062-X

10.1016/S0952-3278(96)90100-3

10.1016/0165-6147(87)90011-3

10.1152/physrev.1992.72.suppl_4.S15

10.1016/S0028-3908(98)00208-1

10.1016/0920-1211(92)90065-2

10.1016/0165-6147(96)10015-8

10.1126/science.7770779

10.1016/0006-8993(86)91464-2

10.1016/0166-2236(95)80030-6

10.1038/367607a0

10.1093/bja/71.1.15

GRYNKIEWICZ G., 1985, A new generation of Ca++ indicators with greatly improved fluorescence properties, J. Biol. Chem., 260, 3440, 10.1016/S0021-9258(19)83641-4

10.1083/jcb.139.7.1785

10.1006/abio.1999.4083

10.1126/science.2581319

HILL M.W., 1998, Inhibition of voltage‐dependent sodium channels by the anticonvulsant γ‐aminobutyric acid type A receptor modulator, 3‐benzyl‐3‐ethyl‐2‐piperidinone, J. Pharm. Exp. Ther., 285, 1303

10.1073/pnas.93.15.8078

10.1016/0041-008X(87)90271-7

LANG D.G., 1993, Lamotrigine, phenytoin and carbamezepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells, J. Pharm. Exp. Ther., 266, 829

LEACH M.J., 1995, Lamotrigine mechanisms of action, 861

10.1093/bja/81.4.491

10.1038/sj.bjp.0701918

LEES G., 1998, Effects of isoflurane and cis‐9,10‐octadecenoamide (cOA) on the ρ1 GABA receptor, J. Physiol. (London), 509, P190

10.1016/0006-8993(93)91660-K

10.1007/PL00005075

MACDONALD R.L., 1986, Anticonvulsant drugs: mechanisms of action., 713

10.1016/0304-3940(89)90485-0

10.1097/00000542-199605000-00025

10.1021/ja01174a081

10.1073/pnas.85.16.6192

10.1097/00000542-199407000-00016

10.1002/(SICI)1097-4547(19971215)50:6<1047::AID-JNR16>3.0.CO;2-1

10.1097/00000539-199806000-00031

Thông tin
Thông tin xuất bản

British Journal of Pharmacology

Tập 129 Số 2

283-290

Thông tin tác giả